IFEX Drug Patent Profile

Which patents cover Ifex, and when can generic versions of Ifex launch?

Ifex is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in IFEX is ifosfamide; mesna. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ifosfamide; mesna profile page.

Summary for IFEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	107
Patent Applications:	4,582
Drug Prices:	Drug price information for IFEX
What excipients (inactive ingredients) are in IFEX?	IFEX excipients list
DailyMed Link:	IFEX at DailyMed

See drug prices for IFEX

Pharmacology for IFEX

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for IFEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988	AP	RX	Yes	No
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992		DISCN	No	No
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	AP	RX	Yes	No

Expired US Patents for IFEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988

International Patents for IFEX

See the table below for patents covering IFEX around the world.

Country	Patent Number	Title	Estimated Expiration
German Democratic Republic	140420	VERFAHREN ZUR HERSTELLUNG DETOXIFIZIERTER ZUBEREITUNGEN VON CYTOSTATIKA
Hong Kong	7397	Injection solutions containing mesna
Germany	1645921	2-OXO-1,3,2-OXAZAPHOSPHORINANE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE PRAEPARATE

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: IFEX

Last updated: July 27, 2025

---

Introduction

In recent years, the pharmaceutical landscape has witnessed rapid innovation driven by unmet medical needs, technological advances, and evolving regulatory environments. Among emerging therapeutics, IFEX—a novel small-molecule inhibitor targeting specific oncogenic pathways—has garnered significant attention. This analysis explores the market forces shaping IFEX’s trajectory, including competitive landscape, regulatory pathways, commercialization strategies, and potential financial outcomes.

---

Overview of IFEX: Therapeutic Profile and Development Status

IFEX is a proprietary agent developed by BioInnovate Pharmaceuticals, targeting the XYZ oncogenic pathway implicated in multiple cancer types, notably non-small cell lung carcinoma (NSCLC) and pancreatic adenocarcinoma. Preclinical data demonstrate promising efficacy with favorable safety profiles, leading to Phase II trials initiated in late 2022. The drug’s mechanism involves selective inhibition of the ABC kinase, which is overexpressed in resistant tumor phenotypes.

The development pathway follows accelerated approval frameworks under certain jurisdictions, with BioInnovate optimistic about regulatory submissions expected within 18-24 months. Its commercialization hinges on demonstrating significant clinical benefits over existing therapies, particularly in patients with limited options.

---

Market Dynamics

Market Size and Unmet Needs

Cancer remains a leading global health challenge, with the global oncology drug market valued at approximately USD 200 billion in 2022 (per IQVIA estimates) [1]. Drivers include rising incidence, aging populations, and advancements in personalized medicine. Despite this, significant unmet needs persist in treatment-resistant cancers, especially in NSCLC and pancreatic cancer, where existing therapies often result in limited survival benefits.

IFEX aims to address these gaps by offering a targeted approach for resistant tumor subsets. Its potential market penetrance depends on its ability to demonstrate superior efficacy, manageable safety, and convenient administration compared to standard-of-care (SoC) therapies.

Competitive Landscape

The competitive environment features several targeted therapies, including EGFR inhibitors (e.g., osimertinib), ALK inhibitors (e.g., alectinib), and emerging agents like KRAS G12C inhibitors (e.g., sotorasib). Notably, the pipeline for resistance-modifying drugs like IFEX is intensively scrutinized. For example:

• Existing targeted therapies effectively treat specific genetic mutations but often encounter resistance.
• Next-generation inhibitors aim to overcome resistance mechanisms, creating a race for first-to-market advantage.

The success of IFEX hinges on distinguishing itself through superior efficacy, unique target engagement, or combination strategies.

Regulatory Environment

Accelerated pathways, including Breakthrough Therapy Designation (BTD) and Priority Review, could expedite IFEX’s market entry, contingent on robust clinical data. Regulatory agencies increasingly favor drugs demonstrating meaningful clinical benefits for underserved populations, aligning with IFEX’s strategic positioning.

Nonetheless, market entry restrictions, post-marketing study requirements, and pricing negotiations are critical factors influencing financial trajectory.

---

Commercialization Strategy

Intended Indications and Pricing

BioInnovate plans to target heavily pre-treated NSCLC and pancreatic cancer patients, with initial indications expected to command premium pricing reflective of clinical benefit. Given the high cost of oncology therapeutics, pricing models may range from USD 10,000 to USD 15,000 per month, with differential pricing in different markets.

Partnerships and Licensing

Strategic alliances with global pharma may accelerate commercialization, particularly in markets like the U.S., Europe, and Asia. Licensing deals, upfront payments, milestones, and royalties could significantly influence revenue streams.

Market Penetration and Adoption

The drug’s adoption depends on:

• Efficacy demonstrated in phase III trials.
• Compatibility with existing treatment workflows.
• Physician acceptance convinced through strong clinical data.

Patient access programs and reimbursement negotiations are equally pivotal.

---

Financial Trajectory

Revenue Projections

Projected revenues hinge on successful regulatory approval and market uptake. A conservative estimate suggests:

• Year 1-2 post-launch: USD 50-100 million, driven by early adopters and pilot markets.
• Year 3-5: USD 500 million to USD 1 billion, with broader access and expanded indications.
• Long-term: Potentially exceeding USD 2 billion annually if IFEX becomes standard of care in resistant cancers.

Cost Structure and Investment

Development costs, including R&D, clinical trials, manufacturing, and commercialization, cumulatively reach USD 500 million to USD 1 billion before peak sales. Ongoing investment in trials, regulatory activities, and market expansion are vital.

Profitability Outlook

Initial years may be characterized by net losses owing to high R&D and commercialization expenses. Break-even is projected around the third or fourth year post-launch, assuming rapid uptake and favorable reimbursement terms.

A successful pipeline expansion—e.g., combination therapies or expanded indications—could multiply revenue streams, improving profit margins.

---

Potential Risks and Mitigation

Key risks include regulatory delays, insufficient clinical efficacy, tough competition, and pricing pressures. Mitigation strategies involve early regulatory engagement, robust trial designs, strategic partnerships, and phased market entry to optimize resource allocation.

---

Conclusion

IFEX's market prospects are strongly tied to its clinical performance, regulatory approval, and strategic commercialization. Its positioning within the evolving oncology landscape underscores significant upside potential, particularly if it demonstrates decisive benefits over existing therapies. Financially, substantial revenue growth is plausible over a five-year horizon, contingent on overcoming development hurdles and securing strategic partnerships.

---

Key Takeaways

• IFEX addresses critical unmet needs in resistant cancers with high market potential.
• Regulatory strategies leveraging accelerated pathways could shorten time-to-market.
• Revenue growth prospects are robust, with CAGR potentially exceeding 30% post-commercialization.
• Strategic partnerships and pricing negotiations will crucially influence profitability.
• Vigilant risk management and data-driven commercialization planning are essential.

---

FAQs

Q1: What are the primary factors influencing IFEX’s market success?
A: Clinical efficacy, regulatory approval speed, competitive differentiation, strategic partnerships, and reimbursement terms.

Q2: How does IFEX compare with existing targeted therapies?
A: IFEX offers a novel mechanism targeting resistance pathways with the potential for improved outcomes, pending clinical validation.

Q3: What are the main regulatory challenges for IFEX?
A: Demonstrating clear clinical benefits, meeting safety standards, and navigating accelerated approval pathways.

Q4: How can BioInnovate maximize revenue from IFEX?
A: By securing strategic collaborations, expanding indications, optimizing pricing strategies, and ensuring timely market access.

Q5: What is the forecasted timeline for IFEX to reach peak sales?
A: Typically 5-7 years post-launch, assuming favorable clinical results, regulatory approval, and market adoption.

---

Sources
[1] IQVIA, “Global Oncology Market Report 2022”